Literature DB >> 12412759

Synergistic effects of locally administered cytostatic drugs and a surfactant on the development of delayed-type hypersensitivity to keyhole limpet haemocyanin in mice.

J Limpens, R J Scheper.   

Abstract

The immunomodulating effects of two locally administered cytostatic drugs, the active cyclophosphamide-derivative Z 7557 and the plant alkaloid VP-16, were compared with the effects of systemically administered cyclophosphamide and several established adjuvants: Freund's complete adjuvant, dextran sulphate, and dimethyl dioctadecyl ammonium bromide (DDA). All agents tested promoted the development of delayed-type hypersensitivity (DTH) to keyhole limpet haemocyanin (KLH) in mice. Locally administered cytostatic drugs were the most effective immunostimulatory compounds, whereas DDA was the least toxic agent tested. In order to increase the effectiveness and/ or reduce the toxicity of these agents we tested the efficacy of combinations of cytostatic drugs and DDA to enhance DTH. The results show that DDA and suboptimal amounts of locally administered cytostatic drugs act synergistically on DTH.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 12412759      PMCID: PMC1534673     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

Review 1.  Suppression of the immune response by microorganisms.

Authors:  J H Schwab
Journal:  Bacteriol Rev       Date:  1975-06

2.  Role of major histocompatibility complex gene products in delayed-type hypersensitivity.

Authors:  J F Miller; M A Vadas; A Whitelaw; J Gamble
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

3.  Enhancement of delayed hypersensitivity by depletion of suppressor T cells with cyclophosphamide in mice.

Authors:  A Mitsuoka; M Baba; S Morikawa
Journal:  Nature       Date:  1976-07-01       Impact factor: 49.962

4.  Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation.

Authors:  A M Claessen; H Valster; H Bril; S Meyer; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 5.  Synergy, additivism and antagonism in immunosuppression. A critical review.

Authors:  M C Berenbaum
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

6.  The role of lipid in the induction of hapten-specific delayed hypersensitivity and contact sensitivity.

Authors:  M O Dailey; R L Hunter
Journal:  J Immunol       Date:  1974-04       Impact factor: 5.422

7.  Delayed hypersensitivity in the mouse.

Authors:  A J Crowle
Journal:  Adv Immunol       Date:  1975       Impact factor: 3.543

8.  Dextran sulphate: an adjuvant for cell-mediated immune responses.

Authors:  R E McCarthy; L W Arnold; G F Babcock
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

9.  The modifying effect of BCG on the immunological induction of T cells.

Authors:  G B Mackaness; P H Lagrange; T Ishibashi
Journal:  J Exp Med       Date:  1974-06-01       Impact factor: 14.307

10.  Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes.

Authors:  M Röllinghoff; A Starzinski-Powitz; K Pfizenmaier; H Wagner
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

View more
  3 in total

1.  Reversal of mucosal tolerance by subcutaneous administration of interleukin-12 at the site of attempted sensitization.

Authors:  A M Claessen; B M von Blomberg; J De Groot; D A Wolvers; G Kraal; R J Scheper
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

2.  Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative.

Authors:  J Limpens; M Van Meijer; H M Van Santen; W T Germeraad; K Hoeben-Schornagel; M Breel; R J Scheper; G Kraal
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

3.  Inhibition of T suppressor cell function by local administration of an active cyclophosphamide derivative at the sensitization site.

Authors:  J Limpens; R J Scheper
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.